Assessment of public opinion on transparency at the US Food and Drug Administration


18 February 2022 - Historically, the US FDA has considered much of the oversight of clinical trials, interactions with companies, and review processes to be confidential. 

In recent years, however, the agency has faced calls for greater transparency, including in its COVID-19 pandemic response and use of expedited review pathways.

Read JAMA article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , Transparency , Data